US · Healthcare · Medical Devices
EPS came in at 0.29 against a street estimate of 0.33 — a miss of 12.1%.
Analysts rate InMode Ltd a hold (0 buy, 5 hold, 0 sell out of 5) with an average price target of $16.17.
| Fund | Stake |
|---|---|
| Doma Perpetual Capital Management LLC | 4.75% |
| Acadian Asset Management LLC | 4.49% |
| BlackRock Inc | 4.34% |
| Renaissance Technologies Corp | 4.16% |
| MENORA MIVTACHIM HOLDINGS LIMITED | 3.55% |
| Steel Partners Holdings LP | 3.18% |
| Millennium Management LLC | 3.04% |
| Morgan Stanley - Brokerage Accounts | 1.94% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On September 15, 2026, an unsolicited, non-binding acquisition proposal for InMode Ltd. expired according to its terms. • The pro | 2026-09-16 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On August 10, 2026, the Haifa District Court in Israel denied in full an urgent request for temporary injunctive relief against In | 2026-08-11 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 GAAP revenue was $95.6 million, essentially unchanged from $95.6 million in Q2 2025. • GAAP net income fell to $17.1 mil | 2026-08-05 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • InMode held its Annual General Meeting on July 30, 2026; all four shareholder proposals were approved. • As of the June 26, 2026 | 2026-08-03 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year covered: year ended December 31, 2025. • InMode has 63,358,750 outstanding ordinary shares. • The company also held | 2026-02-10 |
| Annual report FY2024 (20-F) | 2025-02-04 |
| Annual report FY2023 (20-F) | 2024-02-13 |
| Annual report FY2022 (20-F) | 2023-02-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InMode Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.